Suicidality treatment occurring in paediatrics (STOP) medication suicidality side effects scale in young people in two cohorts across Europe

• Verfasst von: Santosh, Paramala [VerfasserIn]
• Verfasst von: Sala, Regina [VerfasserIn]
• Verfasst von: Lievesley, Kate [VerfasserIn]
• Verfasst von: Singh, Jatinder [VerfasserIn]
• Verfasst von: Arango, Celso [VerfasserIn]
• Verfasst von: Buitelaar, Jan K. [VerfasserIn]
• Verfasst von: Castro-Fornieles, Josefina [VerfasserIn]
• Verfasst von: Coghill, David [VerfasserIn]
• Verfasst von: Dittmann, Ralf [VerfasserIn]
• Verfasst von: Flamarique, Itziar [VerfasserIn]
• Verfasst von: Hoekstra, Pieter J. [VerfasserIn]
• Verfasst von: Llorente, Cloe [VerfasserIn]
• Verfasst von: Purper-Ouakil, Diane [VerfasserIn]
• Verfasst von: Schulze, Ulrike [VerfasserIn]
• Verfasst von: Zuddas, Alessandro [VerfasserIn]
• Verfasst von: Parnell, Nathan [VerfasserIn]
• Verfasst von: Mohan, Mohapradeep [VerfasserIn]
• Verfasst von: Fiori, Federico [VerfasserIn]
• Titel: Suicidality treatment occurring in paediatrics (STOP) medication suicidality side effects scale in young people in two cohorts across Europe
• Verf.angabe: Paramala Santosh, Regina Sala, Kate Lievesley, Jatinder Singh, Celso Arango, Jan K. Buitelaar, Josefina Castro-Fornieles, David Coghill, Ralf W. Dittmann, Itziar Flamarique, Pieter J. Hoekstra, Cloe Llorente, Diane Purper-Ouakil, Ulrike Schulze, Alessandro Zuddas, Nathan Parnell, Mohapradeep Mohan, Federico Fiori
• E-Jahr: 2023
• Jahr: December 13, 2023
• Umfang: 10 S.
• Fussnoten: Gesehen am 10.09.2024
• Titel Quelle: Enthalten in: BMJ open
• Ort Quelle: London : BMJ Publishing Group, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), 12, Artikel-ID e068140, Seite 1-10
• ISSN Quelle: 2044-6055
• DOI: doi:10.1136/bmjopen-2022-068140
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: child & adolescent psychiatry
• Sach-SW: developmental neurology & neurodisability
• Sach-SW: information technology
• Sach-SW: mental health
• Sach-SW: suicide & self-harm
• K10plus-PPN: 1902258037

Abstract

Objectives As part of the ‘Suicidality: Treatment Occurring in Paediatrics (STOP)’ study, we developed and performed psychometric validation of an electronic-clinical-outcome-assessment (eCOA), which included a patient-reported-outcome (ePRO), an observer-rated-outcome (eObsRO) for parents/carers and a clinician-reported-outcome (eClinRO) that allows identification and monitoring of medication-related suicidality (MRS) in adolescents. - Design STOP: Prospective study: A two phase validation study to assess the impact of medication on suicidal ideations. - Setting Six participating countries: Netherlands, UK, Germany, France, Spain and Italy that were part of the Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261411. - Participants Cohort 1 consisted of 41 adolescent-completions, 50 parent-completions and 56 clinician-completions. Cohort 2 consisted of 244 adolescent-completions, 198 parent-completions and 240 clinician-completions from across the six countries. The scale was administered only to participants who have screened positive for the STOP-Suicidality Assessment Scale (STOP-SAS). - Results A total of 24 items for the development of the STOP-Medication Suicidality Side Effects Scale (STOP-MS3) were identified and three versions (for patients, parents and clinicians) of the STOP-MS3 were developed and validated in two separate study cohorts comprising of adolescents, their parents and clinicians. Cronbach’s α coefficients were above 0.85 for all domains. The inter-rater reliability of the STOP-MS3 was good and significant for the adolescent (ePRO), clinician (eClinRO) (r=0.613), parent (eObsRO) versions of the scale (r=0.394) and parent and clinician (r=0.347). Exploratory factor analysis identified a 3-factor model across 24 items for the adolescent and parent version of the scale: (1) Emotional Dysregulation, (2) Somatic Dysregulation and (3) Behavioural Dysregulation. For the clinician version, a 4-factor model defined the scale structure: (1) Somatic Dysregulation, (2) Emotional Dysregulation, (3) Behavioural Dysregulation and (4) Mood Dysregulation. - Conclusion These findings suggest that the STOP-MS3 scale, a web-based eCOA, allows identification and monitoring of MRS in the adolescent population and shows good reliability and validity.